Thromboembolic risks in patients with COVID-19: major concern to consider in our management

Area of Science:

• Cardiovascular Medicine
• Infectious Diseases
• Pathology

Background:

• The COVID-19 pandemic has emerged as a significant cardiovascular risk factor, contributing substantially to global mortality.
• Thromboembolism is strongly implicated as a primary cause of death in COVID-19 patients, linked to vascular inflammation triggered by SARS-CoV-2.
• Currently, no definitive treatment for COVID-19 exists, with many potential therapies undergoing clinical trials.

Discussion:

• The high frequency of thromboembolic events in critically ill COVID-19 patients necessitates a focus on preventative strategies.
• Understanding the mechanisms of SARS-CoV-2-induced vascular inflammation is key to developing targeted interventions.
• The lack of specific treatments underscores the importance of managing secondary complications like thrombosis.

Key Insights:

• COVID-19 acts as an emergent cardiovascular risk factor.
• SARS-CoV-2 infection can cause vascular inflammation, leading to life-threatening thromboembolism.
• Proactive prevention of thromboembolic events is vital for reducing COVID-19 mortality.

Outlook:

• Further research into the pathogenesis of COVID-19-associated coagulopathy is warranted.
• Development and implementation of effective thromboembolism prophylaxis protocols are essential.
• Clinical trials investigating novel therapeutic approaches should prioritize agents targeting vascular inflammation and thrombosis.